COMMUNIQUÉS West-GlobeNewswire

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
28/09/2026
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement NEW [...]
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
28/09/2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
28/09/2026
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program
28/09/2026
Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programs End-to-end supply chain combines 4basebio's proprietary opDNA® enzymatic DNA starting material with TriLink' [...]
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
28/09/2026
Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States Eton has integrated full Eton Cares ® patient support, including $0 co-pay for eligible commercially insured patients [...]
NOTICE TO DISREGARD -- Direct Meds
28/09/2026
New York City, NY, Sept. 28, 2026 (GLOBE NEWSWIRE) -- We are advised by Direct Meds that journalists and other readers should disregard the news release, "Direct Meds Updates DirectMax Clinical Review and Licensed- [...]
Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
28/09/2026
Partnership Expands Flyte’s Growing Presence Across Entertainment, Fashion, Hospitality, Sports and Premium Destination Travel 2026 Flyte Breakthrough Awards will Honor Anthony Ippolito, Star of Amazon MGM Studios’ “I [...]
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
28/09/2026
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat LA JOLLA, Calif., Sept. 28, 2026 [...]
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
28/09/2026
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected to contribute immediately [...]
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
28/09/2026
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with [...]
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
28/09/2026
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors. Dr [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
28/09/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
28/09/2026
Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 Résultats principaux de [...]
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
28/09/2026
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026 The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash [...]

Pages